Sofosbuvir-Velpatasvir-Voxilaprevir Effective in Previously Treated Chronic Hep C
Supporting the results from the blinded portion of the phase 3 primary
study, the single-tablet regimen of sofosbuvir-velpatasvir-voxilaprevir
for 12 weeks was safe, well tolerated, and highly effective in patients
with chronic HCV infection who had previous treatment failure with NS5A
inhibitor-containing regimens. A salvage regimen for this population
represents an important advance for patients with limited retreatment
options.
(link)
